| Literature DB >> 35508657 |
Giacomo Oliveira1,2, Kari Stromhaug3, Nicoletta Cieri3, J Bryan Iorgulescu3,4,5, Susan Klaeger6, Jacquelyn O Wolff7, Suzanna Rachimi6, Vipheaviny Chea8, Kate Krause9, Samuel S Freeman4,6, Wandi Zhang3, Shuqiang Li6,8, David A Braun3,4,6,10, Donna Neuberg11, Steven A Carr6, Kenneth J Livak3,8, Dennie T Frederick6,12, Edward F Fritsch3,6, Megan Wind-Rotolo13, Nir Hacohen4,6,12, Moshe Sade-Feldman6,12, Charles H Yoon3,14, Derin B Keskin3,8,15,16, Patrick A Ott3,4,6,17, Scott J Rodig5,17, Genevieve M Boland4,6,9, Catherine J Wu18,19,20,21.
Abstract
Within the tumour microenvironment, CD4+ T cells can promote or suppress antitumour responses through the recognition of antigens presented by human leukocyte antigen (HLA) class II molecules1,2, but how cancers co-opt these physiologic processes to achieve immune evasion remains incompletely understood. Here we performed in-depth analysis of the phenotype and tumour specificity of CD4+ T cells infiltrating human melanoma specimens, finding that exhausted cytotoxic CD4+ T cells could be directly induced by melanoma cells through recognition of HLA class II-restricted neoantigens, and also HLA class I-restricted tumour-associated antigens. CD4+ T regulatory (TReg) cells could be indirectly elicited through presentation of tumour antigens via antigen-presenting cells. Notably, numerous tumour-reactive CD4+ TReg clones were stimulated directly by HLA class II-positive melanoma and demonstrated specificity for melanoma neoantigens. This phenomenon was observed in the presence of an extremely high tumour neoantigen load, which we confirmed to be associated with HLA class II positivity through the analysis of 116 melanoma specimens. Our data reveal the landscape of infiltrating CD4+ T cells in melanoma and point to the presentation of HLA class II-restricted neoantigens and direct engagement of immunosuppressive CD4+ TReg cells as a mechanism of immune evasion that is favoured in HLA class II-positive melanoma.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35508657 DOI: 10.1038/s41586-022-04682-5
Source DB: PubMed Journal: Nature ISSN: 0028-0836 Impact factor: 49.962